60 Degrees Pharmaceuticals exercises license option for castanospermine

60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP; SXTPW) has exercised an option to negotiate an exclusive license with Florida State University for large-scale purification techniques to extract castanospermine from Australian Chestnut seeds for non-prescription use.

The company plans to develop castanospermine as a botanical product extracted from Castanospermum australe seeds, which have been used as a traditional food source in Australia. The plant grows in Queensland and New South Wales in Australia, as well as Florida, Hawaii, and California.

According to the company, castanospermine modulates carbohydrate metabolism at low doses and has shown effects on disease outcomes in animal studies through immunomodulation at higher doses. The compound is a metabolite of celgosivir, which was previously tested in clinical trials involving more than 500 patients for HIV and Hepatitis C treatment.

Since signing the option agreement with Florida State University in April 2025, 60 Degrees Pharmaceuticals has conducted safety testing and developed prototype capsule formulations for oral delivery. The company stated it is preparing to begin a regulatory process to secure U.S. market access for Australian Chestnut Extract as a non-prescription botanical product.

60 Degrees Pharmaceuticals, founded in 2010, focuses on developing medicines for vector-borne diseases. The company received FDA approval for its malaria prevention product ARAKODA in 2018, which is commercially available in the United States and Australia.

You May Also Be Interested In

• List of suppliers, parts, photos of iPhone 18 Pro are part of Tata Electronics data breach - Reuters
• Unitrend Entertainment plans Nasdaq IPO under ticker INHI
• Arxis (ARXS) 3500 contracts of February 60 calls trade, share price up 3.1%